Are You Up to Date on Your Flu Season Response?
Clinical Practice Guidelines
Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza.
Uyeki TM, et al. Clin Infect Dis. 2019;68(6):e1-e47.
Recommendations for prevention and control of influenza in children, 2021-2022.
Committee on Infectious Diseases. Pediatrics. 2021;148(4):e2021053745.
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2022-23 influenza season.
Grohskopf LA, et al. MMWR Recomm Rep. 2022;71(1):1-28.
Clinician Resources
Influenza (Flu). Centers for Disease Control and Prevention (CDC) website.
Seasonal flu: Information for health professionals.
CDC website
Suggested Readings
Comparison of antiviral agents for seasonal influenza outcomes in healthy adults and children: a systematic review and network meta-analysis.
Liu JW, et al. JAMA Netw Open. 2021;4(8):e2119151.
Baloxavir marboxil for uncomplicated influenza in adults and adolescents.
Hayden FG, et al. N Engl J Med. 2018;379(10):913-923.
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Ison MG, et al. Lancet Infect Dis. 2020;20(10):1204-1214.
Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2).
Baker J, et al. Pediatr Infect Dis J. 2020;39(8):700-705.
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.
Dobson J, et al. Lancet. 2015;385(9979):1729-1737.
Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with influenza A and B viruses: a multicenter randomized controlled study.
Nakamura S, et al. Open Forum Infect Dis. 2017;4(3):ofx129.
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections.
Hayden FG, et al. GG167 Influenza Study Group. N Engl J Med. 1997;337(13):874-880.
Acute myocardial infarction after laboratory-confirmed influenza infection.
Kwong JC, et al. N Engl J Med. 2018;378(4):345-353.
Influenza in the COVID-19 era.
Solomon DA, et al. JAMA. 2020;324(13):1342-1343.
Flexing Your Clinical Management Muscles
Relevant Resources
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCP’s Role in Timely Recognition and Referral
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Improving Patient Outcomes Through Shared Clinical Decision Making
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Best Practices for Screening, Diagnosis, and Management
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies
From the Airway Epithelium to Improved Patient Outcomes
Exercising Best Practices for Hospitalized Patients
Accelerating Diagnosis and Treatment
